STEM CELL THERAPEUTICS REPORTS RESULTS OF NTX-265 TRIAL
Stem Cell Therapeutics has reported positive results from its Phase I pharmacokinetic clinical trial in support of its lead therapeutic program for stroke, NTx-265. The trial demonstrated that, for the two drugs administered to healthy volunteers, no drug related adverse events were encountered and both drugs were detected in the cerebrospinal fluid (CSF) following intramuscular administration.
This Phase I clinical trial permitted characterization of the relationship between intramuscular administration, passage into blood and subsequent transport into the CSF. The study also generated new evidence that these two neural stem cell (NSC) proliferation inducing drugs reach the CSF when administered to human subjects with an intact blood-brain barrier.